NDRC Announces New Announcement: Major Support for These Medical Devices in the Next Three Years
Pharmaceutical News November 29 hearing the latest news, the National Development and Reform Commission formulated and issued a "three-year plan to enhance manufacturing core competitiveness (2018-2020)."
The plan of action proposes that by the end of the 13th Five-Year Plan, key areas of manufacturing industries should break through a number of key and key technologies for industrialization and form a group of leaders with international influence enterprise , Create a batch of well-known brands made in China, create a group of internationally recognized Chinese standards, significantly enhance the manufacturing innovation capability, product quality A substantial increase in overall quality significantly enhanced.
The Action Plan proposes a total of nine key manufacturing sectors that will focus on enhancing core competencies. The 'high end medical instruments And pharmaceutical key technology industrialization 'among them.
In this area, the key tasks of industrialization are:
1, speed up the industrialization and application of high-end medical equipment.
Focus on supporting the industrialization of innovative medical devices such as PET-MRI, ultrasound endoscopy, surgical robots, laboratory-wide automated test and analysis pipeline (TLA).
Supports high-performance imaging devices such as PET-CT, CT and MRI, high-energy linear accelerators and imaging guided radiation therapy devices, high throughput gene sequencing, chemiluminescence immunoassay, and new molecular diagnostic instruments in vitro Diagnostic Products, Total Degradation Coronary Stents, Nerve Stimulators, Tissue Organs Regenerative and Restorative Materials, and other new implantable interventional products, high-end intelligent rehabilitation aids, high-precision real-time inspection system (POCT) and other products upgrading and quality performance improvement.
2, to promote high-end drug Industrialization and application.
It aims at the development and industrialization of innovative drugs that promote targeted diseases, cardiovascular diseases, diabetes mellitus, immune systems, viruses and drug-resistant infections and other major diseases and promote targeted drugs with high selectivity and new mechanism of action.
Support the development and industrialization of the first chemical generic and biologically similar drugs with market potential and high clinical value, and support the upgrading of the product industry through the evaluation of the quality and efficacy of generic drugs.
Support new drugs (new compounds and modified new drugs), new drugs of Chinese medicine category 1-6 (including national medicine) and new classic famous products that have obtained new drug certificate or declared new drug production since 2015, Biopharmaceutical industry listed on the home.
3, to strengthen the construction of specialized technical service platform.
Support the construction of medical equipment and pharmaceutical specialized consulting, research and development, production and application demonstration service platforms, provide public services such as key technology development, standard setting, quality testing and evaluation, clinical research and application demonstration for the industry, promote the comprehensive transformation and upgrading of the industry, and promote Product quality performance improvement and improvement medicine Industry division of labor coordination and production intensification level.
